Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Women’s Health and Affiliated Clinical Conditions
3.2.1. Key Milestones in the Treatment of Women’s Health-related Disorders
3.3. Women’s Health-related Conditions
3.4. Available Treatment Modalities
3.4.1. Surgery
3.4.2. Hormonal Therapies
3.4.3. Non-Hormonal Therapies
3.5. Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Non-hormonal Therapies Market: Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Target Indication
4.2.4. Analysis by Phase of Development and Target Indication
4.2.5. Analysis by Type of Molecule and Target Indication
4.2.6. Analysis by Purpose of Therapy
4.2.7. Analysis by Target Women Population
4.2.8. Analysis by Mechanism of Action
4.2.9. Analysis by Route of Administration
4.3.1. Analysis by Special Designation(s) Awarded

5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Non-hormonal Therapies Market: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geography
5.3. Key Players: Analysis by Number of Product Candidates
5.4. Big Pharma Initiatives

6. KEY COMMERCIALIZATION STRATEGIES
6.1. Chapter Overview
6.2. Successful Drug Launch Strategy: ROOTS Framework
6.3. Successful Drug Launch Strategy: Product Differentiation
6.4. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
6.5. Approved Non-hormonal Prescription Drugs
6.6. Key Commercialization Strategies Adopted by Companies Focused on Women’s Health
6.6.1. Strategies Adopted Before Therapy Approval
6.6.1.1. Participation in Global Events
6.6.1.2. Collaboration with Industry Stakeholders and Other Pharmaceutical Firms
6.6.1.3. Expansion of Target Indication
6.6.2. Strategies Adopted During / Post Therapy Approval
6.6.2.1. Geographical Expansion
6.6.2.2. Participation in Global Events
6.6.2.3. Patient Assistance Programs
6.6.2.4. Awareness Through Product Websites
6.6.2.5. Collaboration with Industry Stakeholders and Other Pharmaceutical Firms
6.6.2.6. Aligning with Government Initiatives to Ensure High Adoption Rate
6.7. Concluding Remarks

7. DRUG PROFILES (PHASE III)
7.1. Chapter Overview
7.2. Relugolix
7.3. DARE-BV1 (Clindamycin gel)
7.4. Ovaprene?
7.5. Yselty? (Linzagolix)
7.6. Fezolinetant
7.7. BAY1002670 (Vilaprisan)
7.8. Abaloparatide-TD
7.9. Terconazole (0.4%)
7.10. SCY-078 (Ibrexafungerp)
7.11. VT-1161 (Oteseconazole)
7.12. MV140 (Uromune)
7.13. Orilissa? (Elagolix)
7.14. EVO100 (Amphora)

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Non-hormonal Therapies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Status
8.3.3. Analysis by Trial Phase
8.3.4. Analysis by Trial Registration Year and Trial Status
8.3.5. Analysis by Target Patient Segment
8.3.6. Analysis by Target Indication
8.3.7. Analysis by Type of Sponsor
8.3.8. Analysis by Geography
8.3.8.1. Analysis by Geography (Pre-2017 and Post 2017)
8.4. Non-Hormonal Therapies: Analysis by Enrolled Patient Population
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Status
8.4.3. Analysis by Trial Phase
8.4.4. Analysis by Geography
8.4.4.1. Analysis by Geography (Pre-2017 and Post 2017)
8.5. Analysis by Study Design
8.6. Concluding Remarks
8.6.1. Emerging Molecules to Watch
8.6.2. Most Important Trials to Watch

9. RECENT DEVELOPMENTS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Non-hormonal Therapies: Recent Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Target Indication
9.3.4. Most Active Players: Analysis by Number of Partnerships
9.3.5. Geographical Analysis
9.3.5.1. Intercontinental and Intracontinental Agreements
9.4. Types of Funding
9.5. Non-Hormonal Therapies: Funding and Investment Analysis
9.5.1. Analysis by Number of Funding Instances
9.5.2. Analysis by Amount Invested
9.5.3. Analysis by Type of Funding
9.5.4. Analysis by Type of Funding and Year
9.5.5. Analysis by Funding Amount and Year
9.5.6. Regional Analysis by Amount Invested
9.5.7. Most Active Players
9.6. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Key Assumptions and Forecast Methodology
10.4. Global Non-hormonal Therapiesfor Women’s Health Market, 2021-2030
10.4.1. Non-hormonal Therapies Market: Analysis by Target Indication
10.4.2. Non-hormonal Therapies Market: Analysis by Type of Molecule
10.4.3. Non-hormonal Therapies Market: Analysis by Route of Administration
10.4.4. Non-hormonal Therapies Market: Analysis by Geography
10.5. Non-hormonal Therapies for Women’s Health Market: Value Creation Analysis
10.5.1. Bacterial Vaginosis
10.5.2. Contraception
10.5.3. Endometriosis
10.5.4. Postmenopausal Osteoporosis
10.5.5. Uterine Fibroids
10.5.6. Vasomotor Symptoms
10.6. Non-hormonal Therapies for Women’s Health Market: Product Wise Sales Forecasts
10.6.1. Nuvessa (Metronidazole)
10.6.1.1. Target Patient Population
10.6.1.2. Sales Forecast
10.6.1.3. Net Present Value
10.6.2. VivaGel (SPL 7013)
10.6.2.1. Target Patient Population
10.6.2.2. Sales Forecast
10.6.2.3. Net Present Value
10.6.3. Solosec (Secnidazole)
10.6.3.1. Target Patient Population
10.6.3.2. Sales Forecast
10.6.3.3. Net Present Value
10.6.4. Tymlos (Abaloparatide)
10.6.4.1. Target Patient Population
10.6.4.2. Sales Forecast
10.6.4.3. Net Present Value
10.6.5. Orilissa
10.6.5.1. Target Patient Population
10.6.5.2. Sales Forecast (Endometriosis)
10.6.5.3. Sales Forecast (Uterine Fibroids)
10.6.5.4. Net Present Value
10.6.6. Osphena (Ospemifene)
10.6.6.1. Target Patient Population
10.6.6.2. Sales Forecast
10.6.6.3. Net Present Value
10.6.7. Evenity(Romosozumab-aqqg)
10.6.7.1. Target Patient Population
10.6.7.2. Sales Forecast
10.6.7.3. Net Present Value
10.6.8. Esmya and Fibristal (Ulipristal acetate)
10.6.8.1. Target Patient Population
10.6.8.2. Sales Forecast
10.6.8.3. Net Present Value
10.6.9. Phexxi (Amphora)
10.6.9.1. Target Patient Population
10.6.9.2. Sales Forecast
10.6.9.3. Net Present Value
10.6.10. Oriahnn
10.6.10.1. Target Patient Population
10.6.10.2. Sales Forecast
10.6.10.3. Net Present Value
10.6.11. Relugolix
10.6.11.1. Target Patient Population
10.6.11.2. Sales Forecast (Uterine Fibroids)
10.6.11.3. Sales Forecast (Endometriosis)
10.6.11.4. Net Present Value
10.6.12. DARE-BV1 (Clindamycin gel)
10.6.12.1. Target Patient Population
10.6.12.2. Sales Forecast
10.6.12.3. Net Present Value
10.6.13. Ovaprene
10.6.13.1. Target Patient Population
10.6.13.2. Sales Forecast
10.6.13.3. Net Present Value
10.6.14. Yselty (Linzagolix)
10.6.14.1. Target Patient Population
10.6.14.2. Sales Forecast (Endometriosis)
10.6014.3. Sales Forecast (Uterine Fibroids)
10.6.14.3. Net Present Value
10.6.15. Fezolinetant
10.6.15.1. Target Patient Population
10.6.15.2. Sales Forecast
10.6.15.3. Net Present Value
10.6.16. BAY1002670 (Vilaprisan)
10.6.16.1. Target Patient Population
10.6.16.2. Sales Forecast
10.6.16.3. Net Present Value
10.6.17. Abaloparatide-TD
10.6.17.1. Target Patient Population
10.6.17.2. Sales Forecast
10.6.17.3. Net Present Value
10.6.18. Terconazole(0.4%)
10.6.18.1. Target Patient Population
10.6.18.2. Sales Forecast
10.6.18.3. Net Present Value
10.6.19. SCY-078 (Ibrexafungerp)
10.6.19.1. Target Patient Population
10.6.19.2. Sales Forecast
10.6.19.3. Net Present Value
10.6.20. VT-1161 (Oteseconazole)
10.6.20.1. Target Patient Population
10.6.20.2. Sales Forecast
10.6.20.3. Net Present Value
10.6.21. MV140 (Uromune)
10.6.21.1. Target Patient Population
10.6.21.2. Sales Forecast
10.6.21.3. Net Present Value
10.6.22. EVO100
10.6.22.1. Target Patient Population
10.6.22.2. Sales Forecast
10.6.22.3. Net Present Value
11. CONCLUDING REMARKS
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES